• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
General Anxiety Disorder - Pipeline Review, H2 2012 Product Image

General Anxiety Disorder - Pipeline Review, H2 2012

  • ID: 2366274
  • December 2012
  • 44 pages
  • Global Markets Direct

General Anxiety Disorder – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'General Anxiety Disorder - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for General Anxiety Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for General Anxiety Disorder. General Anxiety Disorder - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for General Anxiety Disorder.
- A review of the General Anxiety Disorder products under development READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
General Anxiety Disorder Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for General Anxiety Disorder 7
General Anxiety Disorder Therapeutics under Development by Companies 9
General Anxiety Disorder Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
General Anxiety Disorder Therapeutics – Products under Development by Companies 14
General Anxiety Disorder Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in General Anxiety Disorder Therapeutics Development 16
H Lundbeck A/S 16
Mitsubishi Tanabe Pharma Corporation 17
Ironwood Pharmaceuticals, Inc. 18
General Anxiety Disorder – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
tedatioxetine - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
tedatioxetine - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
vortioxetine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MKC-242 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
oxytocin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
IW-2143 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
General Anxiety Disorder Therapeutics – Drug Profile Updates 34
General Anxiety Disorder Therapeutics – Discontinued Products 38
General Anxiety Disorder Therapeutics - Dormant Products 39
General Anxiety Disorder – Product Development Milestones 40
Featured News & Press Releases 40
Jun 29, 2010: Teva Announces Approval Of Generic Effexor XR 40
Aug 22, 2008: Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder 40
Jun 26, 2006: Cephalon Announces Results from GABITRIL(R) Clinical Program in Generalized Anxiety Disorder 41
May 09, 2006: Lilly Submits Cymbalta Supplemental New Drug Application for Generalized Anxiety Disorder 41
Dec 02, 2005: Teva Announces FTC Will Not File Objections To Effexor XR Settlement 42
Apr 13, 2004: Cephalon Announces Plans for Phase III Anxiety Program for GABITRIL in 2004; Results in Phase II Generalized Anxiety Disorder Study Show Efficacy Signal and Suggest Rapid Onset of Effect 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Number of Products Under Development for General Anxiety Disorder, H2 2012 7
Products under Development for General Anxiety Disorder – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
H Lundbeck A/S, H2 2012 16
Mitsubishi Tanabe Pharma Corporation, H2 2012 17
Ironwood Pharmaceuticals, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
General Anxiety Disorder Therapeutics – Drug Profile Updates 34
General Anxiety Disorder Therapeutics – Discontinued Products 38
General Anxiety Disorder Therapeutics – Dormant Products 39

List of Figures
Number of Products under Development for General Anxiety Disorder, H2 2012 7
Products under Development for General Anxiety Disorder – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos